Understanding the course of persistent symptoms in schizophrenia: Longitudinal findings from the pattern study

Imagem de Miniatura
Arquivos
art_HARO_Understanding_the_course_of_persistent_symptoms_in_schizophrenia_2018.PDF (293.04 KB)
Citações na Scopus
31
Tipo de produção
article
Data de publicação
2018
Editora
ELSEVIER IRELAND LTD
DOI
Indexadores
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Autores
HARO, Josep Maria
ALTAMURA, Carlo
CORRAL, Ricardo
EVANS, Jonathan
KREBS, Marie-Odile
ZINK, Mathias
MALLA, Ashok
MENDEZ, Jose Ignacio
BERNASCONI, Corrado
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
PSYCHIATRY RESEARCH, v.267, p.56-62, 2018
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
The Pattern study was conducted to provide longitudinal observational data for individual patients with persistent symptoms of schizophrenia. Pattern is an international, multicenter, non-interventional, prospective cohort study of schizophrenia outpatients who were not considered to be in recovery. In the longitudinal phase reported herein, patients were assessed over 1 year using different clinical rating scales. Patient management followed routine local clinical practice. Primary outcome was disease state, defined by the Positive and Negative Syndrome Scale (PANSS), Negative Symptom Factor Score (NSFS), Positive Symptom Factor Score (PSFS), and Personal and Social Performance (PSP) Scale. In total, 1344 protocol-compliant patients (70.9% male) were included. Patients showed a high stability in disease state between consecutive study visits. Persistent negative persistent symptoms and symptomatic remission were the most prevalent and stable disease states. Patients in relapse generally transitioned to negative persistent symptoms or to symptomatic remission. PANSS, PSP, and quality of life ratings remained relatively stable. Relapses occurred in 10% of patients; probability of relapse was associated with younger age, extra-pyramidal symptoms, and more antipsychotic medications. Despite treatment, schizophrenia symptoms tend to remain stable over time, without overall improvement. One of the greatest challenges in schizophrenia is attainment of full symptom remission.
Palavras-chave
Negative symptoms, Positive symptoms, Naturalistic, Remission, Recovery, Relapse
URI
https://observatorio.fm.usp.br/handle/OPI/29553
Referências
  1. Agid O, 2013, AM J PSYCHIAT, V170, P1335, DOI 10.1176/appi.ajp.2013.12030315
  2. American Psychiatric Association, 2000, DIAGN STAT MAN MENT
  3. Andreasen NC, 2005, AM J PSYCHIAT, V162, P441, DOI 10.1176/appi.ajp.162.3.441
  4. Buchanan RW, 2007, SCHIZOPHRENIA BULL, V33, P1013, DOI 10.1093/schbul/sbl057
  5. Cassidy CM, 2010, SCHIZOPHRENIA BULL, V36, P1001, DOI 10.1093/schbul/sbp007
  6. Chakos MH, 2006, PSYCHIAT SERV, V57, P1094, DOI 10.1176/appi.ps.57.8.1094
  7. Chang WC, 2011, SCHIZOPHR RES, V133, P22, DOI 10.1016/j.schres.2011.09.006
  8. Chue P, 2014, NEUROPSYCH DIS TREAT, V10, P777, DOI 10.2147/NDT.S43404
  9. Csernansky JG, 2002, CNS DRUGS, V16, P473, DOI 10.2165/00023210-200216070-00004
  10. Doering S, 1998, SCHIZOPHRENIA BULL, V24, P87, DOI 10.1093/oxfordjournals.schbul.a033316
  11. Dold Markus, 2015, Evid Based Ment Health, V18, P77, DOI 10.1136/eb-2015-102098
  12. Emsley R, 2011, CURR OPIN PSYCHIATR, V24, P114, DOI 10.1097/YCO.0b013e3283436ea3
  13. *EUROQOL GROUP, 1990, HLTH POLICY, V16, P199, DOI 10.1016/0168-8510(90)90421-9
  14. Fervaha G, 2014, ACTA PSYCHIAT SCAND, V130, P290, DOI 10.1111/acps.12289
  15. Fervaha G, 2014, EUR NEUROPSYCHOPHARM, V24, P1078, DOI 10.1016/j.euroneuro.2014.03.001
  16. Hafner H, 2015, WORLD J PSYCHIATR, V5, P167, DOI 10.5498/wjp.v5.i2.167
  17. Haro JM, 2003, ACTA PSYCHIAT SCAND, V107, P16, DOI 10.1034/j.1600-0447.107.s416.5.x
  18. Haro JM, 2003, ACTA PSYCHIAT SCAND, V107, P7, DOI 10.1034/j.1600-0447.107.s416.4.x
  19. Haro JM, 2003, ACTA PSYCHIAT SCAND, V107, P222, DOI 10.1034/j.1600-0447.2003.00064.x
  20. Harrow M, 2005, SCHIZOPHRENIA BULL, V31, P723, DOI 10.1093/schbul/sbi026
  21. HEGARTY JD, 1994, AM J PSYCHIAT, V151, P1409
  22. HOFFMANN H, 1994, ACTA PSYCHIAT SCAND, V89, P205, DOI 10.1111/j.1600-0447.1994.tb08093.x
  23. Iasevoli F, 2016, PROG NEURO-PSYCHOPH, V65, DOI 10.1016/j.pnpbp.2015.08.010
  24. Jaaskelainen E., 2015, SCHIZOPHR RES TREATM, V2015
  25. Jordan G, 2014, J CLIN PSYCHIAT, V75, pE566, DOI 10.4088/JCP.13m08606
  26. KAY SR, 1987, SCHIZOPHRENIA BULL, V13, P261, DOI 10.1093/schbul/13.2.261
  27. LIDDLE PF, 1987, PSYCHOL MED, V17, P49, DOI 10.1017/S0033291700012976
  28. MALLA AK, 1993, SCHIZOPHR RES, V10, P143, DOI 10.1016/0920-9964(93)90049-O
  29. Marder SR, 1997, J CLIN PSYCHIAT, V58, P538, DOI 10.4088/JCP.v58n1205
  30. Haro JM, 2006, J CLIN PSYCHOPHARM, V26, P571, DOI 10.1097/01.jcp.0000246215.49271.b8
  31. Haro JM, 2015, SCHIZOPHR RES, V169, P234, DOI 10.1016/j.schres.2015.09.001
  32. McGrath J, 2008, EPIDEMIOL REV, V30, P67, DOI 10.1093/epirev/mxn001
  33. Menezes NM, 2006, PSYCHOL MED, V36, P1349, DOI 10.1017/S0033291706007951
  34. Milev P, 2005, AM J PSYCHIAT, V162, P495, DOI 10.1176/appi.ajp.162.3.495
  35. Morosini PL, 2000, ACTA PSYCHIAT SCAND, V101, P323, DOI 10.1111/j.1600-0447.2000.tb10933.x
  36. Norman RMG, 1999, AM J PSYCHIAT, V156, P400
  37. Norman RMG, 2001, BRIT J PSYCHIAT, V179, P340, DOI 10.1192/bjp.179.4.340
  38. Novick D, 2007, PSYCHOPHARMACOLOGY, V191, P1015, DOI 10.1007/s00213-007-0730-2
  39. Novick D, 2009, SCHIZOPHR RES, V108, P223, DOI 10.1016/j.schres.2008.11.007
  40. Owen MJ, 2016, LANCET, V388, P86, DOI 10.1016/S0140-6736(15)01121-6
  41. POSTRADO LT, 1995, PSYCHIATR SERV, V46, P1161
  42. Rabinowitz J, 2012, SCHIZOPHR RES, V137, P147, DOI 10.1016/j.schres.2012.01.015
  43. Robinson D, 1999, ARCH GEN PSYCHIAT, V56, P241, DOI 10.1001/archpsyc.56.3.241
  44. Robinson DG, 2004, AM J PSYCHIAT, V161, P473, DOI 10.1176/appi.ajp.161.3.473
  45. Rutherford BR, 2014, JAMA PSYCHIAT, V71, P1409, DOI 10.1001/jamapsychiatry.2014.1319
  46. San L, 2013, INT J PSYCHIAT CLIN, V17, P2, DOI 10.3109/13651501.2012.687452
  47. Stahl SM, 2004, CURR MED CHEM, V11, P313, DOI 10.2174/0929867043456070
  48. Strauss G.P., 2008, SCHIZOPHRENIA B, V36, P788
  49. Suzuki T, 2014, HUM PSYCHOPHARM CLIN, V29, P414, DOI 10.1002/hup.2421
  50. Suzuki T, 2012, PSYCHIAT RES, V197, P1, DOI 10.1016/j.psychres.2012.02.013
  51. Suzuki T, 2011, SCHIZOPHR RES, V133, P54, DOI 10.1016/j.schres.2011.09.016
  52. Tajima-Pozo Kazuhiro, 2015, F1000Res, V4, P182, DOI 10.12688/f1000research.6699.1
  53. Ventura J, 2015, SCHIZOPHR RES, V161, P407, DOI 10.1016/j.schres.2014.10.043
  54. Ventura J, 2011, SCHIZOPHR RES, V132, P18, DOI 10.1016/j.schres.2011.06.025
  55. White C, 2009, PSYCHOL MED, V39, P1447, DOI 10.1017/S003329170800514X
  56. Wilkinson G, 2000, BRIT J PSYCHIAT, V177, P42, DOI 10.1192/bjp.177.1.42
  57. World Health Organization, 2011, INT STAT CLASS DIS R
  58. Zink M, 2016, LANCET PSYCHIAT, V3, P310, DOI 10.1016/S2215-0366(16)00023-7
  59. Zink M, 2015, EXPERT REV CLIN PHAR, V8, P335, DOI 10.1586/17512433.2015.1040393

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPS